Companies › Incyte
19 active drug programs in 319 registered trials: 184 Phase 2, 91 Phase 1, 42 Phase 3, 2 Phase 4; Oncology, Other, Immunology, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ruxolitinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) … | Nov 2026 |
| INCA033989 unclear - mechanism not stated in registry | – | Phase 3 | Essential Thrombocythemia; Healthy Participants; Myeloproliferative Neoplasms | Nov 2026 |
| povorcitinib JAK1 inhibitor | JAK1 | Phase 3 | Hidradenitis Suppurativa (HS); NonSegmental Vitiligo; Prurigo Nodularis; Moderate to Severe Asthma … | Nov 2026 |
| INCA33890 | – | Phase 3 | CRC (Colorectal Cancer); Solid Tumors | Jan 2027 |
| INCB161734 KRAS G12D inhibitor | KRAS | Phase 3 | Solid Tumors; Healthy Participants | Jan 2027 |
| INCB123667 Cyclin-dependent kinase 4/6 inhibitor (CDK4/6 inhibitor) | – | Phase 3 | Ovarian Cancer; Renal Impairment; Hepatic Insufficiency; Solid Tumors | Jan 2027 |
| Axatilimab Macrophage colony stimulating factor receptor inhibitor | CSF1R | Phase 3 | Chronic Graft-versus-host-disease; TNBC - Triple-Negative Breast Cancer; Hodgkin Lymphoma; Chronic Graft Versus Host Disease … | Jan 2027 |
| Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma; Newly Diagnosed … | Apr 2027 |
| Tafasitamab B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Hematologic Malignancies … | Apr 2027 |
| Itacitinib Tyrosine-protein kinase JAK1 inhibitor | JAK1 | Phase 2 | B-Cell Malignancies; Systemic Sclerosis; Diffuse Large B Cell Lymphoma; Acute Lymphoblastic Leukemia … | Nov 2026 |
| Parsaclisib PI3-kinase p110-delta subunit inhibitor | PIK3CD | Phase 2 | B-Cell Malignancies | Nov 2026 |
| INCB000928 ALK2 (activin receptor-like kinase 2) inhibitor | ALK2 | Phase 2 | Fibrodysplasia Ossificans Progressiva (FOP) | Jul 2027 |
| INCB099280 | – | Phase 2 | Cutaneous Squamous Cell Carcinoma; Advanced Solid Tumor | – |
| INCB186748 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumors | Mar 2027 |
| INCB057643 | – | Phase 1 | Myelofibrosis | Apr 2027 |
| INCA035784 | – | Phase 1 | Myeloproliferative Neoplasms | Mar 2028 |
| INCA036873 | – | Phase 1 | Solid Tumors | Aug 2028 |
| INCB160058 | – | Phase 1 | Myeloproliferative Neoplasms | Oct 2028 |
| INCA036978 | – | Phase 1 | Myeloproliferative Neoplasms | May 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT00098475 | Lenalidomide | Phase 3 | DS Stage I Multiple Myeloma | Oncology | Nov 2008 |
| NCT04460248 | Lenalidomide | Phase 2 | Diffuse Large B Cell Lymphoma | Oncology | Feb 2022 |
| NCT03674047 | Ruxolitinib | Phase 2 | Other Cancer | Oncology | Dec 2022 |
| NCT05182957 | Lenalidomide | Phase 2 | Relapsed/Refractory Peripheral T-cell Lymphoma | Oncology | Dec 2023 |
| NCT03333187 | Ruxolitinib | Phase 2 | Bone Marrow Fibrosis | Oncology | Oct 2024 |
| NCT06719024 | Ruxolitinib | Phase 2 | Vitiligo | Immunology | Jun 2025 |
| NCT04737889 | Lenalidomide | Phase 2 | Primary Central Nervous System Lymphoma | Oncology | Jun 2025 |
| NCT03610971 | Ruxolitinib | Phase 2 | Chronic Phase Chronic Myeloid Leukemia | Oncology | Sep 2025 |
| NCT04551131 | Ruxolitinib | Phase 1 | Hemophagocytic Lymphohistiocytosis | Hematology | Nov 2025 |
| NCT06752694 | Ruxolitinib | Phase 2 | Aplastic Anemia | Hematology | Jan 2026 |
| NCT04789850 | Itacitinib | Phase 2 | Systemic Sclerosis | Immunology | Feb 2026 |
| NCT06261021 | Ruxolitinib | Phase 2 | Discoid Lupus Erythematosus | Immunology | Feb 2026 |
| NCT06399029 | Ruxolitinib | Phase 2 | Exanthema | Oncology | Apr 2026 |
| NCT03104842 | Lenalidomide | Phase 2 | Multiple Myeloma | Oncology | May 2026 |
| NCT03500445 | Lenalidomide | Phase 2 | Myeloma | Oncology | Jun 2026 |
| NCT07725432 | Ruxolitinib | Phase 2 | Immune-related Vitiligo-like-Depigmentation | Immunology | Jul 2026 |
| NCT06756152 | Ruxolitinib | Phase 2 | Biphenotypic Acute Leukemia | Oncology | Jul 2026 |
| NCT03836014 | Lenalidomide | Phase 3 | Multiple Myeloma in Relapse | Oncology | Jul 2026 |
| NCT06762431 | Lenalidomide | Phase 1 | Chronic Lymphocytic Leukaemia (CLL) | Oncology | Aug 2026 |
| NCT07588139 | Ruxolitinib | Phase 1 | Healthy Participants | Other | Sep 2026 |
| NCT07588139 | povorcitinib | Phase 1 | Healthy Participants | Other | Sep 2026 |
| NCT05888844 | INCB099280 | Phase 2 | Cutaneous Squamous Cell Carcinoma | Oncology | Sep 2026 |
| NCT05879822 | INCB099280 | Phase 2 | Advanced Solid Tumor | Oncology | Sep 2026 |
| NCT07814404 | INCB161734 | Phase 1 | Healthy Participants | Other | Oct 2026 |
| NCT04509700 | Ruxolitinib | Phase 2 | B-Cell Malignancies | Oncology | Nov 2026 |
| NCT04509700 | Parsaclisib | Phase 2 | B-Cell Malignancies | Oncology | Nov 2026 |
| NCT04509700 | Itacitinib | Phase 2 | B-Cell Malignancies | Oncology | Nov 2026 |
| NCT07448155 | INCA033989 | Phase 1 | Healthy Participants | Other | Nov 2026 |
| NCT03681561 | Ruxolitinib | Phase 1 | Hodgkin Lymphoma | Oncology | Nov 2026 |
| NCT06517017 | Lenalidomide | Phase 2 | Multiple Myeloma | Oncology | Nov 2026 |
| NCT03980171 | Lenalidomide | Phase 1 | Follicular Lymphoma | Oncology | Nov 2026 |
| NCT04174196 | Lenalidomide | Phase 2 | Plasmacytoma | Oncology | Nov 2026 |
| NCT05851443 | povorcitinib | Phase 2 | Moderate to Severe Asthma | Respiratory | Nov 2026 |
| NCT06199427 | Ruxolitinib | Phase 2 | Inborn Errors of Immunity | Immunology | Nov 2026 |
| NCT05335018 | Lenalidomide | Phase 2 | Relapsed/refractory Diffuse Large B Cell Lymphoma | Oncology | Nov 2026 |
| NCT05491226 | Axatilimab | Phase 2 | TNBC - Triple-Negative Breast Cancer | Oncology | Dec 2026 |
| NCT05979363 | Lenalidomide | Phase 2 | Plasma Cell Leukemia | Oncology | Dec 2026 |
| NCT05992597 | Lenalidomide | Phase 2 | Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma | Oncology | Dec 2026 |
| NCT06547944 | Lenalidomide | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT03223610 | Lenalidomide | Phase 1 | Lymphoma | Oncology | Dec 2026 |
| NCT07049575 | Ruxolitinib | Phase 1 | Hidradenitis Suppurativa | Immunology | Dec 2026 |
| NCT07238712 | Ruxolitinib | Phase 2 | Acute Myeloid Leukemia (AML) | Oncology | Dec 2026 |
| NCT06770842 | Ruxolitinib | Phase 2 | Primary Myelofibrosis (PMF) | Oncology | Dec 2026 |
| NCT03286530 | Ruxolitinib | Phase 2 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT05723055 | Axatilimab | Phase 2 | Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT01208662 | Lenalidomide | Phase 3 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT02544308 | Lenalidomide | Phase 3 | Plasmacytoma | Oncology | Dec 2026 |
| NCT02523040 | Lenalidomide | Phase 2 | Langerhans Cell Histiocytosis (LCH) | Oncology | Dec 2026 |
| NCT04009109 | Lenalidomide | Phase 2 | Myeloma, Multiple | Oncology | Dec 2026 |
| NCT00378105 | Lenalidomide | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT02573896 | Lenalidomide | Phase 1 | Neuroblastoma | Oncology | Dec 2026 |
| NCT01054196 | Lenalidomide | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT02334865 | Lenalidomide | Phase 1 | Partial Response of Multiple Myeloma or Plasma Cell Leukemia | Oncology | Dec 2026 |
| NCT06212999 | povorcitinib | Phase 3 | Hidradenitis Suppurativa (HS) | Immunology | Dec 2026 |
| NCT05817955 | Ruxolitinib | Phase 2 | MDS/MPN | Oncology | Dec 2026 |
| NCT04430894 | Lenalidomide | Phase 2 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT05821088 | Tafasitamab | Phase 2 | Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT05351593 | Tafasitamab | Phase 1 | CNS Lymphoma | Oncology | Dec 2026 |
| NCT01863550 | Lenalidomide | Phase 3 | Plasma Cell Myeloma | Oncology | Dec 2026 |
| NCT06504199 | Lenalidomide | Phase 2 | Mantle Cell Lymphoma | Oncology | Dec 2026 |
The 60 nearest readouts of 319 trials; the rest in the app.
Cash of $3.3bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
JAK1 (3) KRAS (2) JAK2 (1) JAK3 (1) TYK2 (1) CSF1R (1) CD19 (1) CRBN (1) DDB1 (1) CUL4A (1) RBX1 (1) PIK3CD (1)
AbbVie Pfizer Revolution Medicines Eli Lilly Sun Pharmaceutical Industries Alfasigma Takeda LEO Pharma Eisai Bristol-Myers Squibb
Beijing InnoCare Pharma Tech Jazz Pharmaceuticals Exelixis Genmab Shandong Suncadia Medicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.